SMT C1100

DRUG2 trials

Sponsors

Summit Therapeutics

Conditions

Duchenne Muscular DystrophyMuscular Dystrophy, Duchenne

Phase 1

A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

CompletedNCT02056808

Summit TherapeuticsDuchenne Muscular Dystrophy

Start: 2013-11-30End: 2014-07-31Updated: 2014-08-27

Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet

CompletedNCT02383511

Summit TherapeuticsMuscular Dystrophy, Duchenne

Start: 2015-02-28End: 2015-08-31Updated: 2015-08-26

Related Papers

Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy

PLoS ONE2016-04-0753 citations